Pemphigus Vulgaris Clinical Trial
Official title:
A Phase 2 Open-Label Uncontrolled Pilot Study of KC706 in Patients With Stable, Active Pemphigus Vulgaris
Verified date | June 2008 |
Source | Kemia, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine whether KC706 is effective in the prevention and healing of blisters in patients with pemphigus vulgaris, while the patient remains on stable doses of corticosteroids and/or immunosuppressants.
Status | Completed |
Enrollment | 20 |
Est. completion date | June 2008 |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - At least 18 years of age; - Diagnosis of pemphigus vulgaris - Patients must be taking and require either corticosteroid therapy or immunosuppressive therapy or both; - Immunosuppressive therapy, if any,should have been administered at a stable dose for at least 60 days prior to the Baseline Visit and be well-tolerated, without the expectation that there will be a need to increase that dose during the next 30 days; - Corticosteroids, if any, should have been administered at a stable dose for at least 30 days prior to the Baseline Visit without expectation that there will be a need to increase that dose during the next 30 days; - Patients should have active PV skin, scalp or mucosal lesions that meet at least one of the following criteria at the Baseline Visit: - > 3 new lesions/week every week in the previous 3 weeks (skin, scalp, and/or mucosal), with healing occurring at a rate to match the appearance of new lesions; or - At least 3 active, established lesions with a Pemphigus Lesion Score of at least 2; skin or scalp lesions must be = 5mm in diameter to qualify; there is no size requirement for mucosal lesions; or, - 1 large active established skin, scalp, or mucosal lesion > 10 mm; - Accessibility to veins suitable for venipuncture; - Patients must be cooperative, able to read, understand and give informed consent, and able to adhere to the study visit schedule and protocol requirements; and, - Patients must be willing to follow adequate contraceptive measures during the study (both sexes). Exclusion Criteria: - Any history of opportunistic infections within 3 months prior to receiving study drug; - Infection with HIV; - Past or present diagnosis of hepatitis confirmed by serology or elevated hepatic enzymes; - History of alcoholic liver disease or cirrhosis; - Clinically significant concurrent medical disease or laboratory abnormalities evidenced by one or more of the following: - Hepatobiliary AST or ALT = 1.5 × upper limit of normal (ULN);alkaline phosphatase = 1.5 × ULN; or, total bilirubin > 90% of the ULN; - Renal serum creatinine > 1.5 mg/dL; or, significant proteinuria > 2+ on urinary dip test; - Hematologic hemoglobin < 11 mg/dL; leukocytes < 3.5 × 109/L; neutrophils < 1.5 × 109/L; or, platelets < 100 × 109/L; - Presence or history of malignancy; - Uncontrolled diabetes (defined as diabetes requiring hospitalization or emergency care in the 3 months prior to first dose of study drug); - History or suspicion of Gilbert's syndrome; - Significant blood loss (> 500 mL) within 28 days prior to receipt of study drug; - Use of an investigational drug within 30 days of screening, or longer if that drug is expected to have long-acting effects (e.g., modulation of B-cell activity); - Use of Rituximab within the past 6 months; - Use of intravenous IgG within the past 3 months, - Current or recent history (within 12 months of screening) of drug or substance abuse, including alcohol; - Known or suspected pregnancy; nursing mothers; - Clinically significant abnormality on the screening physical examination performed at the Baseline Visit, laboratory testing, vital signs or electrocardiogram suggestive of significant unstable medical condition other than the disease under study; - Condition which, in the opinion of the Investigator, could interfere with participation in the study or would put the patient at unacceptable risk; - History of noncompliance with medical regimens. |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Victoria Werth, MD | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Kemia, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the ability of KC706 to prevent the appearance of new lesions and heal existing lesions, while maintaining stable doses of corticosteroids and/or immunosuppressants in patients with pemphigus vulgaris. | 16 weeks | No | |
Secondary | Evaluate the safety of KC706 in patients with PV and to assess plasma levels of KC706 with once daily dosing. | 16 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04422912 -
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
|
Phase 1 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT04117529 -
Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus
|
N/A | |
Completed |
NCT03334058 -
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
|
Phase 2 | |
Terminated |
NCT03239470 -
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
|
Phase 1 | |
Terminated |
NCT00429533 -
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
|
Phase 2 | |
Recruiting |
NCT05594472 -
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
|
Phase 3 | |
Completed |
NCT02383589 -
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
|
Phase 3 | |
Withdrawn |
NCT03780166 -
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
|
Phase 2 | |
Recruiting |
NCT04096222 -
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
|
||
Not yet recruiting |
NCT03177213 -
Serum IL-21 Levels in Patients With Pemphigus Vulgaris
|
N/A | |
Completed |
NCT00135720 -
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
Completed |
NCT00063752 -
Safety Study of PI-0824 to Treat Pemphigus Vulgaris
|
Phase 1 | |
Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
Terminated |
NCT04598477 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
|
Phase 3 | |
Completed |
NCT02704429 -
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
|
Phase 2 | |
Completed |
NCT00626678 -
Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
|
Phase 2 | |
Active, not recruiting |
NCT05338112 -
Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
|
||
Completed |
NCT06167408 -
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
|
||
Recruiting |
NCT05303272 -
A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
|
Phase 4 |